FOLFOX as adjuvant chemotherapy after curative resection of distant metastases in patients with colorectal cancer

Oncology

Volumn 80, Issue 1-2, 2011, Pages 84-91

  Nozawa, Hiroaki ^a   Kitayama, Joji ^a   Sunami, Eiji ^a   Saito, Shinsuke ^a   Kanazawa, Takamitsu ^a   Kazama, Shinsuke ^a   Yazawa, Kentaro ^a   Kawai, Kazushige ^a   Mori, Ken ^a   Nagawa, Hirokazu ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL INSTITUTE OF OCCUPATIONAL SAFETY AND HEALTH   (Japan)

Author keywords

Adjuvant chemotherapy; Colorectal cancer; Curative resection; FOLFOX; Metastasis

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RELAPSE; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISTANT METASTASIS; DRUG HYPERSENSITIVITY; FATIGUE; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASECTOMY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; PERITONEUM METASTASIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECTUM CARCINOMA; RETROSPECTIVE STUDY; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; LOGISTIC MODELS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 79958766723     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000328761     Document Type: Article

References (21)

1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Ferlay J, Parkin DM, Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-781.
3. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N: Colorectal cancer. Lancet 2010; 375: 1030-1047.
4. Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A, Varchenko M, Juniewicz PE: Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 2000; 58: 920-927.
5. André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116.
6. Sobin LH, Gospodarowicz MK, Wittekind C: TNM Classification of Malignant Tumors, ed 7. Hoboken, John Wiley & Sons, Inc., 2009.
7. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947. (Pubitemid 30644117)
8. Cheeseman SL, Joel SP, Chester JD, Wilson G, Dent JT, Richards FJ, Seymour MT: A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin for advanced colorectal cancer. Br J Cancer 2002; 87: 393-399. (Pubitemid 34983562)
9. Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3rd, Carrato A, Cassidy J, Cervantes A, Fagerberg J, Georgoulias V, Husseini F, Jodrell D, Koralewski P, Kröning H, Maroun J, Marschner N, McKendrick J, Pawlicki M, Rosso R, Schüller J, Seitz JF, Stabuc B, Tujakowski J, Van Hazel G, Zaluski J, Scheithauer W: Capecitabine as adjuvant treatment for Stage III colon cancer. N Engl J Med 2005; 352: 2696-2704. (Pubitemid 41007824)
10. Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N: Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006; 24: 2059-2064. (Pubitemid 46622115)
11. André T, Louvet C, Maindrault-Goebel F, Couteau C, Mabro M, Lotz JP, Gilles-Amar V, Krulik M, Carola E, Izrael V, de Gramont A: CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999; 35: 1343-1347. (Pubitemid 29397434)
12. Common Terminology Criteria for Adverse Events Ver.4.0. Available at URL: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-8.5x11. pdf (accessed on March 25, 2011).
13. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN, Zapas JL, Goodwin JW, Fehrenbacher L, Ramanathan RK, Conley BA, Flynn PJ, Soori G, Colman LK, Levine EA, Lanier KS, Wolmark N: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198-2204. (Pubitemid 46954643)
14. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T, EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK, Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD): Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016. (Pubitemid 351392040)
15. Kanemitsu Y, Kato T, Shimizu Y, Inaba Y, Shimada Y, Nakamura K, Sato A, Moriya Y, Colorectal Cancer Study Group (CCSG) of Japan Clinical Oncology Group: A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone as treatment for liver metastasis from colorectal cancer: Japan Clinical Oncology Group Study JCOG0603. Jpn J Clin Oncol 2009; 39: 406-409.
16. Pfannschmidt J, Dienemann H, Hoffmann H: Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg 2007; 84: 324-338. (Pubitemid 46921128)
17. Riquet M, Foucault C, Cazes A, Mitry E, Dujon A, Le Pimpec Barthes F, Médioni J, Rougier P: Pulmonary resection for metastases of colorectal adenocarcinoma. Ann Thorac Surg 2010; 89: 375-380.
18. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, Langer B, Martignoni G, Bouché O, Lazorthes F, Van Cutsem E, Bedenne L, Moore MJ, Rougier P: Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008; 26: 4906-4911.
19. Mekenkamp LJ, Koopman M, Teerenstra S, van Krieken JH, Mol L, Nagtegaal ID, Punt CJ: Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer 2010; 103: 159-164.
20. Tsai MS, Su YH, Ho MC, Liang JT, Chen TP, Lai HS, Lee PH: Clinicopathological features and prognosis in resectable synchronous and metachronous colorectal liver metastasis. Ann Surg Oncol 2007; 14: 786-794.
21. Gamelin E, Gamelin L, Bossi L, Quasthoff S: Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures . Semin Oncol 2002; 29: 21-33. (Pubitemid 35191038)